POZEN Submits Human Lymphocyte Study For Treximet™ (Formerly Known As Trexima™)
CommentPost ArticleSave to My ArticlesList ArticlesRandom Article
Login is required to access that page
POZEN SUBMITS HUMAN LYMPHOCYTE STUDY FOR TREXIMET™ (FORMERLY KNOWN AS TREXIMA™)Headache / Migraine News From Medical News Today, January 17, 2008
POZEN Inc. (NASDAQ: POZN) announced that it has submitted the findings from the short-term human volunteer study of the genotoxic potential of Treximet™ (formerly known as Trexima™) to the U.S. Food and Drug Administration (FDA).
Comments